1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Articular Cartilage Defect - Pipeline Review, H2 2014

Articular Cartilage Defect - Pipeline Review, H2 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 38 pages

Articular Cartilage Defect - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Articular Cartilage Defect - Pipeline Review, H2 2014’, provides an overview of the Articular Cartilage Defect’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Articular Cartilage Defect, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Articular Cartilage Defect and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Articular Cartilage Defect
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Articular Cartilage Defect and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Articular Cartilage Defect products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Articular Cartilage Defect pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Articular Cartilage Defect
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Articular Cartilage Defect pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Articular Cartilage Defect - Pipeline Review, H2 2014
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Articular Cartilage Defect Overview 6
Therapeutics Development 7
Pipeline Products for Articular Cartilage Defect - Overview 7
Pipeline Products for Articular Cartilage Defect - Comparative Analysis 8
Articular Cartilage Defect - Therapeutics under Development by Companies 9
Articular Cartilage Defect - Therapeutics under Investigation by Universities/Institutes 10
Articular Cartilage Defect - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Articular Cartilage Defect - Products under Development by Companies 14
Articular Cartilage Defect - Products under Investigation by Universities/Institutes 15
Articular Cartilage Defect - Companies Involved in Therapeutics Development 16
Cellular Biomedicine Group, Inc. 16
MediPost Co., Ltd. 17
Vericel Corporation 18
Articular Cartilage Defect - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 21
Drug Profiles 23
human umbilical cord blood-derived mesenchymal stem cells - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
matrix-applied characterised autologous cultured chondrocytes - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
ReJoin - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Stem Cell Therapy for Cerebral Hemorrhage and Articular Cartilage Defect - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Stem Cell Therapy for Osteoarthritis and Articular Cartilage Defect - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Articular Cartilage Defect - Recent Pipeline Updates 29
Articular Cartilage Defect - Dormant Projects 33
Articular Cartilage Defect - Product Development Milestones 34
Featured News and Press Releases 34
Sep 16, 2014: Aastrom Biosciences to Present Three-Year Data From the SUMMIT Extension Study of MACI at the 2015 American Academy of Orthopedic Surgeons Annual Meeting 34
Apr 26, 2013: Genzyme Receives CHMP Recommendation For Approval Of MACI For Treatment Of Articular Cartilage Defect 34
Oct 30, 2012: Duke Researchers Engineer Cartilage From Pluripotent Stem Cells 35
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Tables

Number of Products under Development for Articular Cartilage Defect, H2 2014 7
Number of Products under Development for Articular Cartilage Defect - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Articular Cartilage Defect - Pipeline by Cellular Biomedicine Group, Inc., H2 2014 16
Articular Cartilage Defect - Pipeline by MediPost Co., Ltd., H2 2014 17
Articular Cartilage Defect - Pipeline by Vericel Corporation, H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Route of Administration, H2 2014 20
Number of Products by Stage and Molecule Type, H2 2014 22
Articular Cartilage Defect Therapeutics - Recent Pipeline Updates, H2 2014 29
Articular Cartilage Defect - Dormant Projects, H2 2014 33

List of Figures

Number of Products under Development for Articular Cartilage Defect, H2 2014 7
Number of Products under Development for Articular Cartilage Defect - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 12
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 20
Number of Products by Top 10 Molecule Types, H2 2014 21
Number of Products by Stage and Top 10 Molecule Types, H2 2014 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Stem Cell Assay Market by Type, Kit, Product, Application, End User - Forecast to 2021

Stem Cell Assay Market by Type, Kit, Product, Application, End User - Forecast to 2021

  • $ 6328
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global stem cell assay market is expected to reach USD 1,363.3 million by 2021 from USD 536.6 million in 2016, at a CAGR of 20.5% from 2016 to 2021. Factors such as high prevalence of chronic diseases, ...

Regenerative Medicine Market: By Therapy (Cell Therapy, Gene Therapy, Others), By Product (Autologous Cell-Based, Allogeneic Cell-Based, Acellular), By Application (Orthopaedic & Musculoskeletal Spine, Dermatology, Others) & By Region-Forecast (2016-2021)

Regenerative Medicine Market: By Therapy (Cell Therapy, Gene Therapy, Others), By Product (Autologous Cell-Based, Allogeneic Cell-Based, Acellular), By Application (Orthopaedic & Musculoskeletal Spine, Dermatology, Others) & By Region-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Regenerative medicines are capable of restoring the functionality of cells & tissues by treating a patient with laboratory grown cells and tissues. Regenerative medicines are used in a wide range of degenerative ...

Stem Cell Therapies Market: By Therapy (Autologous & Allogeneic), By Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) & By Geography -Forecast (2016-2021)

Stem Cell Therapies Market: By Therapy (Autologous & Allogeneic), By Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Stem-cell therapy medical practice which is used to treat or prevent a disease or condition using stem cells.Recent inventions and R&D activities have shown that stem cells have tremendous promise to help ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.